MiMedx Group (NASDAQ:MDXG) Hits New 12-Month Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG) reached a new 52-week low on Tuesday . The company traded as low as $3.77 and last traded at $3.86, with a volume of 924041 shares trading hands. The stock had previously closed at $3.81.

Wall Street Analysts Forecast Growth

MDXG has been the subject of several analyst reports. Citigroup initiated coverage on MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Cantor Fitzgerald decreased their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Citizens Jmp initiated coverage on MiMedx Group in a research report on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price objective on the stock. Finally, Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.60.

MiMedx Group Stock Performance

The business’s 50-day simple moving average is $4.83 and its two-hundred day simple moving average is $6.16. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $573.48 million, a price-to-earnings ratio of 12.06 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The firm had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. As a group, sell-side analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of MiMedx Group

Several institutional investors have recently bought and sold shares of the business. World Investment Advisors purchased a new stake in shares of MiMedx Group in the fourth quarter valued at approximately $173,000. Virtu Financial LLC purchased a new position in shares of MiMedx Group during the 4th quarter valued at approximately $78,000. Invesco Ltd. grew its stake in MiMedx Group by 5.9% in the 4th quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock valued at $574,000 after acquiring an additional 4,708 shares during the period. Corient Private Wealth LLC grew its stake in MiMedx Group by 26.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock valued at $316,000 after acquiring an additional 9,614 shares during the period. Finally, Mercer Global Advisors Inc. ADV increased its holdings in MiMedx Group by 33.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock worth $141,000 after acquiring an additional 5,236 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.